Related Experiment Videos
Structure-activity-relationship studies on modulators of the multidrug transporter P-glycoprotein--an overview
Abstract:
Resistance of tumor cells to a wide variety of cytotoxic agents represents a major problem in cancer therapy. In most cases, the cross resistance profile has been shown to be accompanied by a decrease in drug accumulation in the resistant cells. At present it seems to be widely accepted that this decrease in intracellular drug levels is due to active efflux of these drugs caused by P-glycoprotein (PGP). Within the past decade, several substances have been identified as being capable of inhibiting the active drug efflux caused by P-glycoprotein. Although many excellent reviews on the phenomenon of multidrug resistance (MDR) have been published, little is known about SAR (Structure-Activity-Relationship)- or QSAR (Quantitative-Structure-Activity-Relationship)-studies of modulators of MDR. The aim of this article is to review first results in this field.
Insights
Tumor cell resistance to chemotherapy is a major challenge. This review focuses on Structure-Activity Relationship studies of P-glycoprotein modulators, which inhibit drug efflux and overcome multidrug resistance.
Area of Science:
- Pharmacology
- Oncology
- Medicinal Chemistry
Background:
- Tumor cell resistance to cytotoxic agents is a significant obstacle in cancer therapy.
- Decreased intracellular drug accumulation, often due to P-glycoprotein (PGP) mediated efflux, underlies cross-resistance.
- P-glycoprotein (PGP) is a key transporter involved in multidrug resistance (MDR).
Purpose of the Study:
- To review the current state of Structure-Activity Relationship (SAR) and Quantitative Structure-Activity Relationship (QSAR) studies on modulators of P-glycoprotein (PGP).
- To consolidate knowledge on compounds that inhibit P-glycoprotein (PGP) activity and overcome multidrug resistance (MDR).
Main Methods:
- Literature review of published SAR and QSAR studies.
- Analysis of identified P-glycoprotein (PGP) inhibitors and their structure-activity relationships.
Main Results:
- Several substances capable of inhibiting P-glycoprotein (PGP)-mediated drug efflux have been identified.
- Early SAR and QSAR studies provide insights into the molecular mechanisms of P-glycoprotein (PGP) modulation.
Conclusions:
- Understanding SAR/QSAR of P-glycoprotein (PGP) modulators is crucial for developing novel strategies to combat multidrug resistance (MDR).
- Further research in SAR and QSAR is needed to optimize P-glycoprotein (PGP) inhibitors for enhanced cancer therapy.